To constrain costs, strategies have been developed to produce recombinant polyclonal antibodies in a single pot. This process by passes the manufacturing hurdles assocaited with individual antibody production but introduces new challenges to demonstrate reproducbiel cell grwoth, genomic stability, constant antibody ratios and integrity of the component antibodies. Merus solved this by generating Oligoclonics ™ a single PER.C6 stable cell line expressing one light common chain and three heavy cahins, producing consistent antibody mixture with three unique bidning sites at 5020 pg/cell/day for up to 67 cell divisions. The process works since in many cases, light chains are promiscuous, forming functional binding sites with a variety of heavy cahins. In this case, ligand specific heavy chains were selected form a human Fab phage library, containing a single rearranged light chain. (Maynard, Current Opinion in Chemical Engineering, 2013, 2, 405-415).

In another approach, Sympress II, randomly integrates antibody genes into the DHFR CHO DG44 cell line. After gene amplication with mehotrexate, selected high expressing clones were expanded and combined to form a polyclonal master cell bank. This process ahs been evaluated with two groups of six antibodies each, recognizing vaccinia and respiratory syncytial virus. (Maynard, Current Opinion in Chemical Engineering, 2013, 2, 405-415).